Showing results (71-80 of 90) with videos related to
Sort By:
Pageof 9
Molecular Imaging and Biology|May 5, 2019
Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck CancerNaoki Nishio, Nynke S van den Berg, Stan van Keulen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2022
Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell CarcinomaGiri Krishnan, Nynke S van den Berg, Naoki Nishio, et al.Theranostics|June 23, 2021
Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CWGiri Krishnan, Nynke S van den Berg, Naoki Nishio, et al.Oral Oncology|April 19, 2026
Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trialTomoya Yokota, Naomi Kiyota, Takeshi Kodaira, et al.Nature Communications|November 8, 2019
Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancerNaoki Nishio, Nynke S van den Berg, Stan van Keulen, et al.The Lancet. Gastroenterology & Hepatology|May 18, 2020
Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation studyGuolan Lu, Nynke S van den Berg, Brock A Martin, et al.Oral Oncology|May 31, 2024
Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trialYoshinori Imamura, Naomi Kiyota, Makoto Tahara, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2020
Predicting Therapeutic Antibody Delivery into Human Head and Neck CancersGuolan Lu, Shayan Fakurnejad, Brock A Martin, et al.Cancer Medicine|September 30, 2024
Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, et al.Head & Neck|October 2, 2019
Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessmentNaoki Nishio, Stan van Keulen, Nynke S van den Berg, et al.Pageof 9